UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share (URGN)

CUSIP: M96088105

Q4 2025 13F Holders as of 31 Dec 2025

Security type / class
Equity / Ordinary Shares, par value NIS 0.01 per share
Total 13F shares
43,711,574
Total 13F value
$1,023,591,933
Holder snapshot 6 visible 7 signals
Share change
-54,776
Put/Call ratio
15%
SEC-reported price per share
$23.42
Number of holders
167
Value change
+$14,662,063
Number of buys
81
Open additional details 1 more signal available
Number of sells
75
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
48,684,257

Security key

M96088105

Report period

Q4 2025

Institutions

167

Top holders

10

URGN full security history Ownership snapshot Full 13F holder table Newer quarter: Q1 2026 Previous quarter: Q3 2025 UroGen Pharma Ltd. SEC filings UroGen Pharma Ltd. company facts

Broader feeds

Latest 13F filings Latest 13D/G filings Investors directory

Ownership snapshot

Top reported holders of URGN - UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
MORGAN STANLEY
Disclosed value leader
RTW INVESTMENTS, LP
Comparable rows
15/15
Latest evidence
30 Sep 2025
13F 13D/G Lead comparable stake: 5.4% 13D/G row: MORGAN STANLEY Showing 1-6 of 15 holder rows.

Quick read

MORGAN STANLEY leads the comparable SEC ownership view at 5.4%.

15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens MORGAN STANLEY's linked filing trail.
Comparable ownership Top 5
MORGAN STANLEY 5.4%
MENORA MIVTACHIM HOLDINGS LTD. 5%
Soleus Capital Master Fund, L.P. 4.7%
Adage Capital Management, L.P. 2.8%
Monograph Capital Holdings Adviso... 1.8%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
MORGAN STANLEY
13F 13D/G
Company
13F 13D/G
5.4%
from 13D/G
$50,442,497
2,528,446 shares
 — 30 Sep 2025
MENORA MIVTACHIM HOLDINGS LTD.
13D/G 13F
Company
13D/G 13F
5%
$24,780,614
2,303,031 shares
 $0 11 Mar 2025
Soleus Capital Master Fund, L.P.
13D/G
13D/G
4.7%
$31,114,400
2,185,000 shares
 -$1,993,600 30 Jun 2025
Adage Capital Management, L.P.
13D/G
13D/G
2.8%
$13,740,520
1,277,000 shares
 -$17,765,685 31 Mar 2025
Monograph Capital Holdings Advisors, LLC
13D/G
Monograph Capital Partners I, L.P.
13D/G
1.8%
$8,503,556
838,615 shares
 $0 05 Jun 2025
RTW INVESTMENTS, LP
13F
Company
13F
9.3%
$90,650,705
4,543,895 shares
 — 30 Sep 2025
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q4 2025

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
167
Shares
43,711,574
Rows available
167
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q4 2025 vs Q3 2025 Across Filers

Q3 2025 holders
159
Q4 2025 holders
167
Holder diff
8
Investor Q3 2025 Shares Q4 2025 Shares Share Diff Share Chg % Q3 2025 value Q4 2025 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .